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Abstract
Imbalance of pro-inflammatory and anti-inflammatory cytokines was detected in 104 examined the patients with chronic
hepatitis C. These changes were the most significant in patients with concomitant diabetes mellitus (DM) type II. Achievement
of sustained viral response (SVR) under the influence of antiviral therapy depends on the state of cytokines system. This was
evidenced by the detected correlation relationship between the levels of viral load (VL) in patients with concomitant diabetes
mellitus type II, namely, direct weak one between IL-4 and VL (r = 0.21) and reverse weak one between the level of IL-2
and VL (r = -0.04). Virus elimination rate and frequency influenced by anti-viral therapy (AVT) depends on the balance of
pro-inflammatory and anti-inflammatory cytokines. This was shown in the research by detection of direct medium correlation
relationship between VL and IL-4 (r= 0.31) and reverse medium correlation relationship between VL and IL-2 (r= -0.45).
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Problem statement and analysis of the
recent research
Chronic hepatitis C (CHC) currently remains an extremely
important medical and social problem of modern medicine [1,
14, 15]. The peculiarity of the problem is certainly the fact
that HCV infection lasts without significant clinical symptoms
for a long time causing its late diagnosis in 75-85% of cases
at the stage of already developed chronic form with further
rapid progression to hepatic cirrhosis (HC) and hepatocellular
carcinoma (HCC) [13, 14].
In the 90s of the last century the study of factors influenc-
ing the course and efficacy of antiviral therapy (AVT) detected
that carbohydrate metabolism disorders such as DM type II,
hyperglycemia in the fasted state, impaired glucose tolerance
and insulin resistance (IR) disorder were often observed in pa-
tients with chronic hepatitis C [1, 5]. Currently, world literary
sources provide sufficient data indicating the correlated im-
pact of HCV infection and carbohydrate metabolism disorders
[2, 11, 12]. Many studies have found that viral hepatitis C
(VHC) is a “metabolic” virus able to induce IR development
(especially genotype 1) in case of normal and even under-
weight body mass regardless of the presence of metabolic
factors. The presence of hepatic steatosis regardless of its
form (induces, metabolic or combined virus) IR, and diabetes
mellitus (DM) type II in this group of patients worsens the
prognosis regarding fibrosis progression rate in CHC [1, 2, 3]
and are the markers of CHC specific therapy ineffectiveness
according to EASL data. Experimental study of foreign scien-
tists [21] has also demonstrated that hyperinsulinemia itself
leads to increased replication of HCV in vitro [8, 11, 21].
Peculiarities of CHC course depend on immunopatholog-
ical reactions [4, 6, 9]. However, unfortunately the immune
system in the majority of patients with CHC is unable to elimi-
nate the virus allowing it to replicate in hepatocytes for a long
time [7, 20]. In recent years, the immune response as effector
phase of immune reactions has been proven to be regulated
by soluble mediators, namelt cytokines. Cytokines coordinate
important processes in the liver such as hepatocyte growth
and regeneration, inflammatory processes, the development
of fibrosis and cirrhosis [6, 13, 18]. The majority of domestic
and foreign authors studying basic pathogenic mechanisms of
disorders in CHC have noted with significant difference the
decrease in the concentration of pro-inflammatory cytokines
in contrast to their increase in case of normal functioning of
the immune system and simultaneous increase in the content
of anti-inflammatory cytokines. High level of IL-4 in case of
decrease in IL-2 level in blood serum was studied to be asso-
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ciated with long-term persistence of HCV in the body, high
activity of infectious process [9, 10]. In addition, according
to many researchers’ data the crucial role in the pathogenesis
of many structural and functional disorders in patients with
DM (hepatopathy, insulin resistance, vessel wall disorders)
belongs to cytokine system imbalance [16].
Thus, we consider the determination of the prevalence
of immune response type with the production of certain cy-
tokines to be the basis not only for more accurate understand-
ing of the pathological process and CHC prognosis but also
for the effectiveness of treatment [17, 19]. Currently, the need
to develop “maintenance” therapy when conducting specific
AVT which would provide sustained viral response through
the correction of the main pathogenetic changes (namely, cy-
tokine system) is an important therapeutic issue regarding
CHC for many foreign researchers.
The objective of the research was to study the impact of
alpha-lipoic acid and lactulose on the effectiveness of antivi-
ral therapy in patients with CHC and concomitant diabetes
mellitus type II.
1. Methods
104 patients with CHC were examined. The course of the
disease associated with diabetes mellitus type II was observed
in 84 patients. 20 patients with CHC without comorbidities
constituted the experimental group. 84 patients with com-
bined pathology underwent the specific combined antiviral
therapy with pegylated interferon alpha-2b and alpha-2a in
combination with ribavirin according to international recom-
mendations for the treatment of chronic hepatitis C EASL
(2006, 2009, 2012, 2013) and “Chronic Hepatitis C” (2014),
unified clinical protocols of primary, secondary (specialized)
care for adults and children. Treatment duration constituted
48 weeks according to international recommendations as the
study included patients with genotype 1b. The dose of pegy-
lated interferon alpha-2b was determined in an amount of 1.5
µg/kg once per week. Ribavirin dose required for combina-
tion therapy with pegylated interferon alpha-2b was calculated
according to patient body weight. In combination with antivi-
ral therapy (AVT) the patients were prescribed alpha-lipoic
acid in a dose of 300 mg/day intravenously by drop infusion
per 200.0 ml of 0.9% sodium chloride solution for 10 days
with subsequent transition to oral administration of the medi-
cation in a dose of 1 capsule (300 mg) in the morning for 60
days. Taking into account the impact of intestinal dysbacte-
riosis on the severity of major clinical symptoms the intensity
of the imbalance of lipid peroxidation / antioxidant defense
systems and cytokines, we used lactulose in the treatment
regimen in a dose of 6.66 g once daily in the morning for two
months.
Patients with CHC and concomitant DM type II were
divided into 4 groups depending on the treatment. 20 patients
(Group I) received only AVT. 21 patients (Group II) received
alpha lipoic acid (ALA) in addition to AVT. 23 patients (Group
III) received lactulose in addition to AVT. 20 patients (Group
IV) received ALA and lactulose according to the proposed
regimen along with AVT. The control group consisted of 20
apparently healthy individuals.
Monitoring of AVT effectiveness and safety was con-
ducted on the basis of international recommendations on the
management of patients with CHC undergoing standard AVT
(EASL 2006, 2012-2014) on the 4th week of treatment (rapid
viral response – RVR), after 12th week (early virological re-
sponse – EVR), 24th week after the therapy completion (sus-
tained viral response – SVR).
Along with the assessment of viral response, the assess-
ment of biochemical responses achievement was conducted
according to EASL (2006, 2012-2014) recommendations. Ef-
ficacy of the treatment was assessed according to the dynamics
of viral load reduction during the treatment and 24 weeks after
the treatment.
The main role in the pathogenesis of disorders and de-
velopment of complications and extrahepatic manifestations,
virus elimination and the disease progression in HCV infec-
tion is known to belong to the balance of the cytokine system.
The importance of studying this mechanism of changes is
caused also by the fact that DM type II, hepatopathy and
multisystemic changes in this pathological condition are also
based on IL system disorder. Therefore, the levels of IL-2 and
IL-4 were determined in all patients in 2 weeks, 2, 6 and 12
months of treatment in addition to general clinical methods of
examination.
Titers of cytokines were determined by ELISA test on the
analyzer “Stat Fax 303 Plus” (USA) using standard reagents
kit “Vektor Best” (Russia) in the Central laboratory for HIV
infection, toxoplasmosis, venereal diseases and viral hepati-
tis diagnostics at the Regional Center of HIV Infection Pre-
vention and AIDS Control at Regional Clinical Infectious
Hospital in Ivano-Frankivsk.
All patients were included into the research after signing
an informed consent.
Statistical processing of the research results was con-
ducted on a PC using a standard package Statistica 5. Mean
values (M), mean error (m), significance of differences ac-
cording to Student’s t-test were assessed. Pearson correlation
coefficient was used to assess interrelation between the studied
characteristics.
2. Results and Discussion
According to the results of the conducted research, the level
of IL-4 was increased in all groups of patients before the treat-
ment in comparison with that in healthy individuals (p<0.001).
The level of pro-inflammatory cytokine IL-2 in serum was
significantly lower (by 3.2 times on average) in patients with
CHC and concomitant DM type II compared to the control
group (p<0.001) (Fig. 1). Comparison of IL-2 indices in
patients with CHC and concomitant DM type II and in patients
with CHC without comorbidity detected that IL-2 level in the
main group was 1.2 times lower than in the comparison group
(3.85±0.37 pg/ml and 3.12±0.15 pg/ ml (p<0.01) (Fig. 1).
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Figure 1. Indicators of cytokine profile in patients with
CHC with concomitant DM type II.
Reverse weak correlation relationship between the levels of
IL-2 and IL-4 (r=-0.23) was also observed in the main group.
Thus, the presence of concomitant DM type II in patients
with CHC affects the provision of cellular response to the pres-
ence of HCV infection, therefore contributing to the disease
progression.
Clear direct weak correlation relationship between the
level of viral load in patients with concomitant DM type II
and IL-4 (r=0.21) and reverse weak correlation relationship
between the level of IL-2 and VL (r=-0.04) was established
in the course of the research. That is, the process activity,
pathogen elimination and the effectiveness of AVT depend on
interleukins system balance, especially in case of combined
pathology which enhances the inhibition of cell protection
system.
The frequency of virologic response achievement by pa-
tients with CHC and concomitant DM type II depending on
the treatment regimen is shown in Figure 2.
RVR was achieved with almost the same frequency in
all studied groups. Negative result of PCR RNA VHC was
recorded in 10 patients of Group I (50.00±10.95%), 12 pa-
tients of Group II (57.14±10.80%), 10 patients of Group III
(43.48±10.34%), 14 patients of Group IV (70.00±10.25%)
in 4 weeks of the treatment. RVR in the patients of group IV
occurred with the same frequency as in patients with CHC
without comorbidities (p>0.05), which was not observed in
the other groups. RVR was recorded in 45% of patients of
group I, 47.62% of patients of group II, 39.13% of patients of
group III and in 50% of patients of group IV with no signifi-
cant difference between groups.
SVR was achieved in 8 patients (40.00%) who were pre-
scribed ALA and lactulose in addition to AVT which was
2 times higher in comparison with group I (40.00±4.47%
versus 20.00±8.94%), 2.09 times higher than in group II
(40.00±4.47% versus 19.05±8.22%), 2.2 times higher in com-
parison with group III (40.00±4.47% versus 18.18±8.57%)
(p>0.05). Significant difference between the study groups
was not detected (p>0.05).
Figure 2. The frequency of virologic response achievement
under the influence of the treatment.
Dependence of virus elimination rate and frequency on
the balance of pro-inflammatory and anti-inflammatory cy-
tokines was proven as a result of detection of direct medium
correlation relationship between VL and IL-4 (r=0.31) and
reverse medium correlation relationship between VL and IL-2
(r=-0.45).
3. Conclusions
• Increase in IL-4 level by 3.8 times and decrease in IL-2
level by 2.6 times was observed in patients with CHC
compared to the control group.
• Imbalance of pro-inflammatory and anti-inflammatory
cytokines was the most significant in patients with con-
comitant diabetes mellitus type II. Comparison of these
interleukins levels between the groups proved that IL-4
index was 1.3 times higher in patients with concomitant
DM type II than in the group without comorbidities
(9.87±0.19 pg/ml versus 7.63±0.37 pg/ml, p<0.001)
and IL-2 level was 1.3 times lower than in the com-
parison group (3.85±0.37 pg/ml and 3.11±0.16 pg/ml
(p<0.05).
• Sustained viral response was achieved in 25.00% of pa-
tients who were prescribed AVT, in 28.57% of patients
who were prescribed ALA in addition to AVT and in
26.09% of patients who were treated with lactulose in
addition to AVT. Inclusion of ALA and lactulose into
the treatment increased SVR to 45%.
• Dependence of virus elimination rate and frequency on
the balance of pro-inflammatory and anti-inflammatory
cytokines was proven as a result of detection of direct
medium correlation relationship between VL and IL-4
(r=0.31) and reverse medium correlation relationship
between VL and IL-2 (r=-0.45).
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